East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Oxcarbazepine Extended-Release Tablets, 150 mg, 300 mg, and 600 mg. Aurobindo Pharma’s Oxcarbazepine Extended-Release Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Oxtellar XR Tablets manufactured by Supernus Pharmaceuticals, Inc.

Oxcarbazepine Extended-Release Tablets are indicated for the:

• Treatment of partial-onset seizures in patients 6 years of age and older.